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Background: The societal burden caused by anxiety disorders has likely been underestimated, while those for
schizophrenia and depression have received more attention. Anxiety disorders represent a significant illness
category that occurs at a high prevalence and poses a considerable burden. However, the cost of anxiety disorders
in Japan has not yet been well researched. The goal of the present study was to estimate the total cost of anxiety
disorders in Japan and to clarify the characteristics of this burden.
Method: A prevalence-based approach was adopted to measure the total cost of anxiety disorders. Anxiety
disorders were defined as diagnosis code F40.0-F41.9 according to the International Statistical Classification of
Diseases and Related Health Problems, 10th Revision. The cost was comprised of the following components:
medical treatment costs and social service costs as direct costs, and morbidity and mortality costs as indirect costs.
Data were collected from publicly available statistics.
Results: The total cost of anxiety disorders in Japan in 2008 was JPY 2.4 trillion (US$ 20.5 billion at the current
exchange rate of US$1 = JPY 116.8). The direct cost was JPY 50 billion. The morbidity cost was JPY 2.1 trillion, while
the mortality cost was JPY 0.24 trillion.
Conclusions: The social burden caused by anxiety disorders in Japan is tremendous and is similar to that of other
mental disorders. Productivity loss in the workplace represents the largest portion of all the cost components.
Because the medical examination rate is quite low, the improvement of healthcare access might contribute to cost
mitigation.
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Mental illness has become an issue of serious concern.
According to a WHO survey conducted in 2010, an esti-
mated 450 million persons worldwide suffer from mental
or behavioral diseases [1], posing a considerable burden
on society. In Japan, for example, the accrued cost of de-
pression in 2005 was JPY 2.0 trillion (USD 18 billion) [2],
while that of schizophrenia in 2008 was JPY 2.8 trillion
(USD 24 billion) [3]. Anxiety disorders also represent a
significant illness category that occurs at a high preva-
lence and that poses a considerable burden. For example,
the 12-month prevalence rates of anxiety disorders were* Correspondence: kyoshimu@hpm.med.keio.ac.jp
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reproduction in any medium, provided the orestimated to be over 10% in the US and Europe (18.1% in
the US [4]; 13.6% in Europe [5]). Although the prevalence
of anxiety is estimated to be lower in Japan (5.5%), it re-
mains twice as high as that of depression [6]. As for the
societal burden caused by anxiety disorders, the burden
was estimated to be within the range of USD 42.3 billion
to USD 46.6 billion in the U.S. in 1990 [7,8] and approxi-
mately GBP 1.2 billion in England in 2007 [9].
A tendency for indirect costs to constitute the major
portion of the total costs was common among these
studies. Therefore, a precise estimation of the indirect
and direct costs is essential for evaluating the societal
cost of this illness category. The cost of anxiety disorders
in Japan has not yet been researched adequately.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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This study attempted to estimate the cost caused by
anxiety disorders in Japan in 2008, so as to provide in-
formation regarding the extent of the societal burden
posed by anxiety disorders.
Methods
A prevalence-based approach was used to measure the
total costs caused by anxiety disorders among adults
over 20 years of age in Japan in 2008. Data for 2008 were
used, as this was the most recent year for which all the
necessary data were available. Anxiety disorders were de-
fined as diagnosis code F40.0-F41.9 according to the
International Statistical Classification of Diseases and
Related Health Problems, 10th Revision (ICD-10). The
total cost was comprised of the following components:
healthcare costs and social service costs as direct costs,
and morbidity and mortality costs as indirect costs. The
informal care cost was excluded because of the lack of a
reliable means of estimating this cost in Japan. This
study was conducted from a societal perspective. Data
were collected from publicly available statistics and re-
ports. We have acknowledged the possibility that data
derived from these statistics varied depending on the
year surveyed, since the data were estimated using a ran-
dom sampling method. Therefore, when previous data
were available [10,11], the data were checked and the
stability of the data was confirmed. Analyses were con-
ducted according to conservative principles (i.e., the
avoidance of overestimates). The results are shown in
both Japanese yen (JPY) and US dollars (USD). The Pur-
chasing Power Parity between JPY and USD for 2008
(USD 1 = JPY 116.8) was used to calculate the USD
equivalent of each cost component.
Direct costs
Healthcare costs covered by health insurance
To calculate the healthcare costs covered by health insur-
ance, we mainly used two Ministry of Health, Labour and
Welfare data sources: the Patient Survey [10] and the Sur-
vey of Medical Care Activities in Public Health Insurance
[11]. In Japan, universal healthcare is provided under pub-
lic health insurance schemes. The volume of services pro-
vided under these schemes is reported annually by the
Survey of Medical Care Activities in Public Health Insur-
ance [11], while the number of patients (categorized ac-
cording to diagnosis) utilizing healthcare services within
these schemes is estimated every three years by the Patient
Survey [10]. Briefly, the Patient Survey estimated the
number of patients in each diagnostic category for all
physical and mental diseases, while the Survey of Medical
Care Activities in Public Health Insurance showed the
treatment expenses covered by public health insurance in
each diagnostic category. Regarding anxiety disorders, theSurvey of Medical Care Activities in Public Health Insur-
ance showed the total combined outpatient costs for all
F4 group disorders, including panic disorders, social anx-
iety disorders, somatoform disorders, dissociative disor-
ders and so on; thus, the costs specifically associated with
anxiety disorders were not indicated. Accordingly, the
proportion of patients with anxiety disorders among all
the patients with F4 group disorders was calculated so as
to examine the costs associated only with anxiety disor-
ders, assuming that the average outpatient cost among pa-
tients with different F4 group disorders was the same.
Healthcare costs covered by health insurance included
all costs needed to provide each healthcare service, such
as salaries for physicians and staffs, medical devices, medi-
cations, overhead costs, training costs, and so on.
Outpatient cost
Outpatient cost data were collected from the Patient Sur-
vey [10] and the Survey of Medical Care Activities in Pub-
lic Health Insurance [11]. However, the Survey of Medical
Care Activities in Public Health Insurance [11] showed
only the combined medical costs for F4 group disorders
(neurotic, stress-related, and somatoform disorders); thus,
the specific costs caused by anxiety disorders could not be
estimated. As for the data from the Patient Survey [10],
the proportion of patients with anxiety disorders
among all the patients diagnosed as having F4 disor-
ders was calculated, and the proportional cost caused
by anxiety disorders alone per month was calculated
from the total healthcare cost for F4 disorders, as-
suming that the average outpatient costs for the dif-
ferent F4 disorders were the same. The formula
shown below was used to calculate the annual out-
patient costs:
Canx−out ¼ Cf 4−out  Nanx−outNf 4−out  12;
where Canx-out is the outpatient cost of anxiety disor-
ders, Cf4-out is the outpatient cost of the F4 group,
Nanx-out is the estimated number of outpatients with
anxiety disorders, and Nf4-out is the estimated number
of outpatients with F4 group diagnoses.Inpatient cost
Inpatient cost data were also obtained from the
Patient Survey [10] and the Survey of Medical Care
Activities in Public Health Insurance [11]. To calcu-
late the proportion of patients with anxiety disorders
among all the patients diagnosed as having F4 disor-
ders and the proportional cost for anxiety disorders
alone per month, the same method as that used to
calculate the outpatient cost was applied. The formula
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patient cost:
Canx−in ¼ Cf 4−in  Nanx−inNf 4−in  12;
where Canx-in is the inpatient cost of anxiety disorders,
Cf4-in is the inpatient cost of the F4 group, Nanx-in is the
estimated number of inpatients with anxiety disorders,
and Nf4-in is the estimated number of inpatients with F4
group diagnoses.
Medication cost
The medication cost was regarded as the total cost of
any medications prescribed for patients with a diagnosis
of anxiety disorder. The medication cost data were col-
lected from the Patient Survey [10] and the Survey of
Medical Care Activities in Public Health Insurance [11].
Because of the above-mentioned limitation of the Survey
of Medical Care Activities in Public Health Insurance
[11], the same method (i.e., utilizing the Patient Survey)
as that used to calculate the outpatient and inpatient
costs was applied. The formulas used to calculate the in-
patient and outpatient medication costs are shown below:
Canx−in−m ¼ Cf 2−in−m  Nanx−inNf 2−in  12; and
Canx−out−m ¼ Cf 4−out−m  Nanx−outNf 4−out  12;
where Canx-in-m and Canx-out-m are the inpatient and out-
patient medication costs of anxiety disorders, Cf4-in-m and
Cf4-out-m are the inpatient and outpatient medication costs
of the F4 group, Nanx-in and Nanx-out are the estimated num-
bers of inpatients and outpatients with anxiety disorders,
and Nf4-in and Nf4-out are the estimated numbers of inpa-
tients and outpatients with F4 group diagnoses, respectively.
Medication costs covered by the “Diagnosis Procedure Com-
bination/Per-diem Payment System” (DPC/PDPS) were ex-
cluded from the inpatient medication costs calculated above,
as these costs had already been included in the inpatient cost
of anxiety disorders calculated in the previous section.
Involuntary admission cost
As described by Sado et al. [3], two distinct types of for-
mal admission exist: ‘medical protection admission’ and
‘involuntary admission' . Therefore, a patient can be ad-
mitted to a hospital through three pathways in Japan: 1)
a voluntary admission, to which the patient consents; 2)
a ‘medical protection admission’, which occurs when a
designated psychiatrist acts in compliance with the “Law
Related to Mental Health and Welfare of Persons with
Mental Disorders” and judges a patient to have a mental
disorder requiring inpatient treatment and the patient’sguardian agrees to the admission and treatment, even
though the patient himself/herself might not provide
consent; and 3) an ‘involuntary admission' , which occurs
when the assessments of two independent, designated
psychiatrists conclude that a patient has a mental illness
and presents a risk to himself/herself or to others.
The Law Related to Mental Health and Welfare of Per-
sons with Mental Disorders, which is similar in some
ways to the UK’s Mental Health Act of 1983, is described
by the Law Society as follows: The Law Related to Men-
tal Health and Welfare of the Person with Mental Dis-
order, similar in some ways to the UK’s Mental Health
Act 1983, is described by the Law Society thus: The law
to provide person(s) with mental disorder with medical
care and protection, and in combination with the Law to
Support Independence of Disabled Persons to offer ne-
cessary assistance for promoting their social rehabilita-
tion, self-support and participation in socio-economic
activities, and to endeavor to prevent onset thereof,
maintain and promote mental health of the people in
general, to thereby advance general well-being of the
person(s) with mental disorder and to enhance mental
health of the people in general [12].
Under the arrangements for voluntary admissions
and ‘medical protection admissions' , the costs are met
by health insurers in the usual way; thus, the costs are
included in the inpatient admission costs described
above. However, ‘involuntary admission’ costs are met
by a separate budget that is directly funded by tax-
payers and thus needs to be added to the inpatient
costs described above.
The involuntary admission cost was estimated as fol-
lows. Using data from the Mental Health and Welfare
Document [13], we obtained the number of involuntary
admissions per day and multiplied this number by the
healthcare costs per day; this value was then multiplied
again by 365 (the number of days in a year). The medical
cost per day for involuntary admission was assumed to
be the same as the hospital costs for patients with F4
disorders, as estimated by the Survey of Medical Care
Activities in Public Health Insurance [11].
Costs of provision under the Medical Care and
Supervision Act in Japan
The Medical Care and Supervision Act in Japan defines
the provision of appropriate medical care and treatment
to promote social rehabilitation for persons who have
committed serious crimes under the condition of insan-
ity or diminished capability [14]. The budget for the exe-
cution of mental health supervision and the execution of
medical care provision under the Medical Care and
Supervision Act in Japan was used as the starting point
to calculate the cost of provision under the Medical Care
and Supervision Act in Japan. The rate of patients with
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the Medical Care and Supervision Act in Japan was not
available but was calculated by hypothesizing that the
rate of the number of F4 group patients among all the
psychiatric patients and the rate of the number of pa-
tients with anxiety disorders among all the F4 group
patients under the Medical Care and Supervision Act in
Japan would be the same as the rate of the number of F4
group patients among all the psychiatric patients admit-
ted involuntarily [13] and the rate of the number of
patients with anxiety among all the F4 group patients
under the health insurance schemes from the Patient
Survey [10], respectively.
Social service cost
The social service cost represents the cost of services
provided under the Services and Supports for Persons
with Disabilities Act. The cost of all the services pro-
vided under the Services and Supports for Persons with
Disabilities Act was regarded as the total social service
costs. As described by the Ministry of Health, Labour
and Welfare, this Act aims to improve the welfare of
persons (adults) and children with disabilities through
the provision of benefits for necessary disability wel-
fare services and the provision of other forms of sup-
port to enable persons (adults) and children with
disabilities to live independent daily or social lives
according to their respective abilities and aptitudes
[15]. The costs of other social services provided out-
side the scope of this act, such as the medical assist-
ance costs covered by public assistance (i.e., financial
support for medical treatment costs by local govern-
ment for those receiving public assistance) and the
costs for health centers and group homes, should be
included in this cost; however, these components had
to be excluded from the analysis because of the lack of
available data. The associated data used to calculate
this cost were obtained from a Mental Health and Wel-
fare Document [13] and a study titled “Survey of pa-
tients with mental disorders attending mental health
clinics who are not involved in social activities cur-
rently, and research to improve the support of patients
wishing to become involved in social activities” con-
ducted in 2007 by the Japanese Association of Mental
Health Services (ASUKURI research) [16]. The services
provided under the Services and Supports for Persons
with Disabilities Act include those that provide places
and opportunities for employment (type A support)
or training without an employment contract (type B
support) for patients with disabilities who have diffi-
culty obtaining employment from for-profit organiza-
tions. First, we added the number of those who use
support for continuous employment (type A) or sup-
port for continuous employment (type B). Then, weapplied data on the frequency of use to each diagnosis
in the ASUKURI research [16] and calculated the total
number of people using these offices per year, multi-
plying the total number by the cost per single use.
Indirect costs
The indirect costs were comprised of the morbidity cost
(including absenteeism, presenteeism and unemploy-
ment cost) and the mortality cost. Morbidity costs occur
when patients are not able to function normally as a
result of their illness [17], while mortality costs arise
when patients die as a result of suicide at an age earlier
than the average life expectancy.
Morbidity cost
Morbidity cost represents the loss resulting from a de-
cline in the productivity of employees with anxiety dis-
orders (i.e., absenteeism and presenteeism) and the
loss resulting from the lack of employment of patients
with anxiety disorders (i.e., unemployment cost).
Absenteeism and presenteeism To estimate absentee-
ism and presenteeism resulting from anxiety disorders,
first we estimated absenteeism arising from each of
the disorders that are classified as anxiety disorders (i.e.,
agoraphobia, panic disorder, social anxiety disorder
[SAD], specific phobias, and generalized anxiety disorder
[GAD]), by multiplying the number of patients for each
sex and age group by the average number of days of
suspension from employment and the expected daily
earning, then adding up the costs for each sex and age
group.
The number of patients was estimated according to
sex and age by multiplying the population, according to
sex and age, and the 12-month prevalence rate. The
12-month prevalence rate, according to sex and age, and
the average number of days of suspension from employ-
ment were retrieved from the World Mental Health
survey of Japan (WMH-J) report (Tables 1 and 2) [6].
The expected daily earning was calculated based on the
Basic Survey on Wage Structure [18] and the Monthly
Labour Survey [19] (Table 3). The formula used to cal-
culate the cost of absenteeism for each sex and age
group was as follows:
Cab ¼ Po  Pr  Dab W ;
where Cab is the cost of absenteeism, Po is the popula-
tion size, Pr is the 12-month prevalence of anxiety disor-
ders, Dab is the average number of days of suspension
from employment, and W is the expected average daily
earning.
On the other hand, we were not able to obtain reliable
data for presenteeism in Japan. Therefore, similar to the
Table 1 Prevalence and standard error (SE) of anxiety disorders for age and sex
Male Female
Age Prevalence SE Distribution Prevalence SE Distribution
Agoraphobia 20-34 0.012 0.006 beta 0.017 0.007 beta
35-44 0.005 0.004 beta 0.007 0.005 beta
45-54 0.003 0.003 beta 0.004 0.003 beta
55-64 0.002 0.002 beta 0.003 0.002 beta
65- 0.001 0.002 beta 0.002 0.002 beta
SAD 20-34 0.018 0.008 beta 0.014 0.006 beta
35-44 0.013 0.007 beta 0.010 0.005 beta
45-54 0.009 0.005 beta 0.007 0.004 beta
55-64 0.004 0.003 beta 0.003 0.003 beta
65- 0.004 0.003 beta 0.003 0.002 beta
Specifc Phobia 20-34 0.032 0.010 beta 0.045 0.011 beta
35-44 0.034 0.011 beta 0.048 0.012 beta
45-54 0.028 0.009 beta 0.040 0.009 beta
55-64 0.021 0.007 beta 0.030 0.008 beta
65- 0.017 0.006 beta 0.024 0.006 beta
Panic Disorder 20-34 0.005 0.004 beta 0.009 0.005 beta
35-44 0.005 0.004 beta 0.008 0.005 beta
45-54 0.007 0.004 beta 0.013 0.005 beta
55-64 0.001 0.001 beta 0.001 0.002 beta
65- 0.017 0.006 beta 0.024 0.006 beta
GAD 20-34 0.010 0.006 beta 0.016 0.006 beta
35-44 0.010 0.006 beta 0.016 0.007 beta
45-54 0.009 0.005 beta 0.014 0.006 beta
55-64 0.006 0.004 beta 0.010 0.005 beta
65- 0.003 0.002 beta 0.005 0.003 beta
Calculated by the authors based on the data derived from Kawakami (2006).
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duct a literature review to determine the relative ratio of
days of presenteeism versus those of absenteeism. Stud-
ies were included in the results of the literature review if
they met the following conditions:Table 2 Lost work days for each anxiety disorder and relative r
absenteeism




Specifc Phobia 1.3(0.84) gamma
Panic 7.3(6.14) gamma
GAD 8.7(2.88) gamma
Derived from Kawakami (2006). an observational study performed in a large,
representative, community sample taken from the
general population, and
 the rates of absenteeism and presenteeism were
measured directly from the samples, and anxietyatio of day-equivalents for presenteeism versus







Table 3 Expected daily earnings
male female
Age JPY distribution JPY distribution
20-24 12,788 deterministic 11,515 deterministic
25-29 16,180 deterministic 13,872 deterministic
30-34 19,411 deterministic 14,796 deterministic
35-39 22,777 deterministic 15,752 deterministic
40-44 25,992 deterministic 16,251 deterministic
45-49 27,686 deterministic 15,625 deterministic
50-54 27,731 deterministic 15,265 deterministic
55-59 25,631 deterministic 14,310 deterministic
60-64 17,484 deterministic 11,746 deterministic
65-69 14,586 deterministic 11,097 deterministic
70- 16,178 deterministic 12,444 deterministic
Derived from Basic Survey on Wage Structure.
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diagnostic classification system, such as the ICD, or
DSM, to distinguish anxiety from ill-defined psycho-
logical distress or stress as an outcome.
We excluded studies using workplace samples because
such studies were unlikely to represent a diversity of
vocations. The evidence was further restricted to peer-
reviewed, published, English language reports. We per-
formed the literature review using PubMed and the
following search terms: anxiety disorder, absenteeism,
presenteeism, and productivity loss. As a result, only one
article [20] met the above-mentioned criteria for inclu-
sion in the search results. Briefly, this study estimated
the cost of lost productivity due to a variety of medical
conditions, such as allergic rhinitis, anxiety disorders,
depression, hypertension, and so on, using data from
8,267 US employees at 47 employer locations. The
results showed that the cost of presenteeism associated
with anxiety disorders was 3.26 times higher than that of
absenteeism.
The number of equivalent days of presenteeism was
thus calculated by multiplying the number of workdays
lost because of absenteeism by the relative ratio of days
lost as a result of presenteeism versus the number of
days lost because of absenteeism using the formula
shown below:
Dpr ¼ RR Dab;
where Dpr is the number of equivalent days of presentee-
ism, RR is the relative ratio of days lost due to presentee-
ism versus the number of days lost due to absenteeism(i.e., 3.26), and Dab is the average number of days of sus-
pension from employment.
The estimated number of equivalent days of present-
eeism was then combined with the number of days lost
because of absenteeism. The cost of absenteeism and
presenteeism associated with each disorder was then
estimated by multiplying the number of patients, the
total equivalent days of both absenteeism and present-
eeism, and the average daily earning for each age range
using the formula shown below:
Cab þ Cpr ¼ Po  Pr  Dab þ Dpr
 W ;
where Cab + Cpr is the cost of absenteeism and present-
eeism, Po is the population size, Pr is the 12-month
prevalence of anxiety disorders, Dab is the average num-
ber of days of suspension from employment, Dpr is the
number of equivalent days of presenteeism, and W is
the expected daily earning.
Finally, by combining the costs of each disorder, the
total costs of absenteeism and presenteeism for anxiety
disorders as a whole was estimated. During the morbid-
ity cost calculation, a variety of uncertain parameters
were used. To reflect the uncertainty of the results,
a probabilistic sensitivity analysis (PSA) [21,22] was
conducted to estimate the mean cost and its 95% confi-
dential interval (CI). The details of this method are
described in the ‘Uncertainty’ section below. All the
parameters and their distributions that were included in
the model to calculate absenteeism and presenteeism
are shown in Tables 1, 2, and 3.
Unemployment cost
Regarding the unemployment cost, we estimated this
cost for each sex and age group by multiplying the
number of patients, the difference in the percentage of
employment between the general population and the
patients, and the average yearly earning using the fol-
lowing formula:
UC ¼ Po Pr  Egen–Eanx
 W ;
where UC is the unemployment cost, Po is the popula-
tion size, Pr is the point prevalence of anxiety disor-
ders, Egen is the employment rate of the general
population, Eanx is the employment rate of patients
with anxiety disorders, and W is the average yearly
earning. The total unemployment cost was estimated
by summating each category of sex-age-specific un-
employment costs.
The number of patients in each sex and age group was
calculated by multiplying the population [23] by the
prevalence rate [6]. On the other hand, the employment
rate for each sex and age group was calculated based on
the ASUKURI research database [16] for patients with











20-24 0.639 deterministic 0.435 (0.101) beta 3,184 deterministic
25-29 0.885 deterministic 0.630 (0.070) beta 4,029 deterministic
30-34 0.924 deterministic 0.717 (0.058) beta 4,833 deterministic
35-39 0.934 deterministic 0.667 (0.059) beta 5,672 deterministic
40-44 0.941 deterministic 0.733 (0.051) beta 6,472 deterministic
45-49 0.941 deterministic 0.746 (0.056) beta 6,894 deterministic
50-54 0.929 deterministic 0.759 (0.078) beta 6,905 deterministic
55-59 0.892 deterministic 0.714 (0.075) beta 6,382 deterministic
60-64 0.725 deterministic 0.379 (0.089) beta 4,353 deterministic
65-69 0.478 deterministic 0.400 (0.096) beta 3,632 deterministic











20-24 0.648 deterministic 0.380 (0.068) beta 2,815 deterministic
25-29 0.718 deterministic 0.548 (0.058) beta 3,392 deterministic
30-34 0.617 deterministic 0.469 (0.062) beta 3,618 deterministic
35-39 0.622 deterministic 0.435 (0.051) beta 3,851 deterministic
40-44 0.687 deterministic 0.394 (0.060) beta 3,973 deterministic
45-49 0.729 deterministic 0.333 (0.056) beta 3,820 deterministic
50-54 0.698 deterministic 0.451 (0.069) beta 3,732 deterministic
55-59 0.600 deterministic 0.311 (0.059) beta 3,499 deterministic
60-64 0.425 deterministic 0.135 (0.047) beta 2,872 deterministic
65-69 0.255 deterministic 0.075 (0.036) beta 2,713 deterministic
70- 0.085 deterministic 0.075 (0.036) beta 3,043 deterministic
*1 Derived from Labour force survey.
*2 Derived from ASUKURI reseach.
*3 Employment rate of the patients with anxiety disorders was assumed to follow Beta distribution. All other parateters were deterministic values.
*4 Derived from Basic Survey on Wage Structure.
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the general population, We assumed that the employ-
ment rate of patients with anxiety disorders who do not
receive treatment was the same as that of the general
population. Thus, we estimated the employment rate of
the patients with anxiety disorders to be as follows:
Eanx ¼ Eanx−tre  Racc þ Eanx−ntre  1−Raccð Þð Þ;
where Eanx is the employment rate of the patients with
anxiety disorders, Eanx-tre is the employment rate of the
patients with anxiety disorders who receive treatment,
Eanx-ntre is the employment rate of the patients with
anxiety disorders who do not receive treatment, andRacc is the rate of the patients with anxiety disorders
who access treatment (i.e. 0.139 [S.E. 0.023] [6]).
When estimating the unemployment cost, we used vari-
ous uncertainty parameters. To reflect the uncertainty of
the result, we performed a PSA and calculated the mean
cost and its SE. The PSA method is described in detail in
the Sensitivity analysis section. The parameters inputted
in the calculation of the unemployment cost are shown in
Table 4.Mortality cost
The definition of mortality cost was the net present
value (NPV) of the expected lifetime earnings loss
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cost was calculated by multiplying the estimated number
of suicides arising from anxiety disorders by the NPV of
the expected lifetime earnings. The NPV was calculated






where q is the age at the time of death by suicide, n is
the age of the patient if they had survived, l is the life ex-
pectancy, En is the employment rate at the age of n, Wn
is the average yearly earning at the age of n, and i is the
discount rate.
The total number of suicides was obtained from the
Statistics of Suicide of the National Police Agency [25].
The rate of anxiety disorders among the subjects who
had committed suicide was obtained from Kaga’s data
[26], published in 2009. The reason that this ratio was
chosen was that although the sample size was relatively
small (n = 76), a psychological autopsy had been con-
ducted for 76 of the suicides, and the demographic data
of the sample was representative of the data for all the
suicide cases in Japan.
The expected lifetime earning was calculated based on
the Basic Survey on Wage Structure [18] and the Labor
Force Survey [24]. First, the average monthly wage of
the general population of employees (regularly providedTable 5 Parameters for calculation of mortality cost
Male
age the number of
suicides *1
distribution expected lifetime earnin
(JPY: thousand)* 2
20-29 2,373 deterministic 121,766
30-39 3,396 deterministic 119,104
40-49 3,852 deterministic 94,737
50-59 4,986 deterministic 52,633
60- 7,639 deterministic 11,489
unkown 204 deterministic 63,317
Female
age the number of
suicides *1
distribution expected lifetime earnin
(JPY: thousand)* 2
20-29 1,065 deterministic 57,818
30-39 1,454 deterministic 50,972
40-49 1,118 deterministic 38,805
50-59 1,377 deterministic 20,822
60- 4,154 deterministic 4,704
unkown 20 deterministic 24,791
*1 Derived from Statistics of Suicides in 2008.
*2 Derived from Basic Survey on Wage Structure.
*3 Derived from Kaga.cash wages) was calculated for each sex and age group.
Then, the expected lifetime earning of the general popu-
lation was calculated. Second, the employment rate for
each sex and age group was obtained from the Labor
Force Survey [24], and the NPV of the expected lifetime
earning was calculated by multiplying the employment
rate by the expected lifetime earning of the employee.
The mortality cost per suicide was regarded as the NPV
of the expected lifetime earning of the general popula-
tion from the age at death until the average life span
(that is, if the person who committed suicide had lived
and had reached the average life span).
The discount rate was set at 3%, as this figure has
been used frequently in recent international research
[27]. Similar to the estimation of the morbidity cost, un-
certain parameters (such as the rate of patients with
anxiety disorders among the suicides) were included in
the calculation of the mortality cost, and we performed
a PSA to calculate the average and SE of the mortality
cost. The details of the PSA are described in the Sensi-
tivity Analysis section. The parameters used to calculate
the mortality cost are shown in Table 5.Sensitivity analysis
The best available evidence was collected to estimate the
cost of anxiety disorders. However, many of the parame-
ters used for the estimations had constant uncertainties.g distribution the rate of suicides caused by
anxiety disorders (S.E.) *3
distribution
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
g distribution the rate of suicides caused by
anxiety disorders (S.E.) *3
distribution
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
deterministic 0.149 (0.041) beta
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PSA [21,22] and calculated the mean and SE of the costs
caused by anxiety disorders.
The probability distribution of each parameter of the
indirect cost is shown in the references or was pre-
scribed based on the SE calculated for that cost. The
PSA was performed using 5,000 micro-simulations with
the macro-function of Excel 2007. Each parameter in




The direct cost caused by anxiety disorders in Japan in
2008 was estimated to be JPY49.7 billion (USD 426
million). The medical care cost was JPY 49.4 billion
(USD 423 million), while the involuntary admission
cost was JPY 19.0 million (USD 163,000), the cost of
the Medical Care and Supervision Act in Japan was
JPY 27.0 million (USD 231,000), and the social service
cost was JPY 244 million (USD 2.09 million). The de-
tails are shown in Table 6.
Indirect costs
Morbidity cost
Absenteeism and presenteeism The average number of
days and its SE for suspension from employment de-
pending on each disorder were as follows: agoraphobia,
7.3 (6.14); SAD, 7.3 (6.14); specific phobia, 1.3 (0.84);
panic disorder, 7.3 (6.14); and GAD, 8.7 (2.88) (Table 2)
(days lost caused by agoraphobia and panic disorder
were assumed to be the same as that of SAD because of
the lack of available data). As previously described, a lit-
erature review for the ratio of presenteeism/absenteeism
identified only one article. The result was a ratio of 3.26.
A PSA was conducted using the parameters shown in
Tables 1, 2, and 3. As a result, the average number of
days of suspension from employment resulting from the
absenteeism and presenteeism of patients with anxiety
disorders was estimated (Table 2). The results of theTable 6 Direct cost
In
Health care cost
Health care cost under health insurance schema
Treatment cost
Medication cost
Involantary admission cost The medical care and
supervision act cost
Social service cost
TotalPSA showed that the productivity loss from absenteeism
and presenteeism for patients with anxiety disorders was
estimated as JPY 1.38 trillion (USD 11.8 billion)
(Table 7).
Unemployment cost
The employment rates of the general population and of
subjects with anxiety disorders and the expected yearly
earnings are shown in Table 3. By multiplying the num-
ber of patients, the difference in the percentage of em-
ployment between the general population and patients,
and the average yearly earning, the lost employment
costs were estimated, since the 12-month prevalence
rate and the employment rate of the patients with
anxiety disorders used in the estimation contained some
uncertainty. Therefore, to reflect this uncertainty, a PSA
was implemented. The results revealed that the mean
unemployment cost related to anxiety disorders was
JPY 718 billion (SE: JPY 2.07 billion) (USD 6.15 billion
[SE: USD 17.7 million]) (Table 7).
Mortality cost
The total number of suicides in Japan in 2008 was
31,638. The mortality cost was estimated by multiplying
the rate of patients with anxiety disorders among the
suicides from Kaga’s data [26] by the number of sui-
cides for each sex and age group, and then multiplying
this figure by the expected lifetime earning. The rate of
patients with anxiety disorders among all suicides con-
tained some uncertainty. Therefore, to reflect this un-
certainty in the results, a PSA was implemented, and
the mean mortality cost and its SE were calculated. The
results revealed that the mean mortality cost of anxiety
disorders was JPY 244 billion (SE: JPY 944 million)
(USD 2.09 billion [SE: USD 8.08 million]) (Table 7).
Discussion and conclusions
From the results of this research, the total cost of anx-
iety disorders was estimated to be about JPY 2.39 trillion










Table 7 Indirect cost
(JPY: million)
mean S.E.
Morbidity cost 2,099,089 6,950
Absenteeism and presenteeism 1,381,347 6,465
Unemployment cost 717,743 2,070
Mortality cost 244,395 944
Total indirect cost 2,343,484 7,008
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about JPY 2.34 trillion (USD 20.0 billion) (Table 8).
Thus, indirect costs accounted for the major part of the
total cost (Figure 1). In analyzing the costs of illness, it
is difficult to conduct a direct comparison with other
studies, as the cost categories included in the estimation
and/or the estimation method differ among studies.
Nonetheless, it became clear that in Japan, as in previ-
ous reports from overseas, the indirect costs constituted
the major part of the total cost [7-9]. Furthermore, the
estimated proportion of the direct cost in Japan was
even lower than that in previous studies [7-9]. As one
reason, we consider that the number of patients who ac-
tually consulted a medical institution is likely to be
lower in Japan than in other countries. For example, in
McCrone’s study [9], there were about 1,000,000 pa-
tients who were treated, whereas in the Patient survey
[10], there were only about 500,000 adult patients. This
difference probably affected the direct cost. However,
the direct cost in Japan is still relatively low, even after
adjustment for the lower number of patients. The rea-




Health care cost 49,442
Health care cost under health insurance schema 49,396
Involuntary admission cost 19
The medical care and supervision act cost 27
Social service cost 244
Indirect cost 2,343,484
Morbidity cost 2,099,089
Absenteeism and Presenteeism 1,381,347
Unemployment cost 717,743
Mortality cost 244,395
Total cost 2,393,170of patients might be shorter in Japan. Regardless of this
difference, one of the characteristic features of the costs
of anxiety disorders is that the cost of indirect damage
caused by the disease (indirect cost) is larger than the
cost of treatment of the disease itself (direct cost).
On the other hand, what is the status of other mental
disorders? Previous studies [3,28] have estimated the
costs of schizophrenia and depression, respectively,
using the same methodology as that used in the present
study. As already implied by Sado et al. [3], a compari-
son of the results of the present study with those from
previous studies indicates that for all 3 of these mental
disorders, the indirect cost accounted for the greater
part of the total cost (73% for schizophrenia; 91% for
depression; and 98% for anxiety disorders).
Furthermore, when components of the indirect cost
were examined, the costs caused by absenteeism and
presenteeism constituted the largest component, ac-
counting for about 59% of the whole. The unemploy-
ment cost was about 31%, and the mortality cost was
about 10%. Similarly, in regard to the indirect cost com-
ponent for other mental disorders, in the case of depres-
sion, the cost for absenteeism and presenteeism was
about 53%, the unemployment cost was about 17%, and
the mortality cost was about 30%. For schizophrenia, the
unemployment cost was about 92% and the mortality
cost was about 8%; absenteeism and presenteeism were
not included as cost components in that estimation.
However, as already discussed by Sado et al. [3], consid-
ering the low employment rate and the low prevalence
rate of patients with schizophrenia, compared with those
of patients with depression or anxiety disorders (both
approximately one third of the employment rate and the
prevalence rate of depression) [3,28], even if the costs ofte or Mean S.E.













Figure 1 Proportion of each cost component.
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a large influence on the proportion of the indirect cost.
Based on these findings, when the cost caused by anx-
iety disorders is compared with that caused by other
mental disorders, the decline in productivity as a result
of absenteeism and presenteeism is the greatest for anx-
iety disorders. This is another unique feature of the cost
of anxiety disorders.
According to the report of the WMH-J [6], the
medical examination rate for anxiety disorders was
about 14%, and this low medical examination rate
may be another reason for the increased indirect cost.
Therefore, the rate of medical care accessibility must
be increased to provide proper medical treatment to
individual patients and to reduce the costs caused by
anxiety disorders, especially indirect costs.
Limitations
Anxiety disorders are often considered to coexist
with other mental disorders; however, we could not
estimate the influence of this possibility of a dual
diagnosis on the precision of the obtained data. This
was one of the study limitations. Concerning the
morbidity cost, this parameter was estimated using
prevalence data from the WMH-J [6], and while the
prevalence rate for each anxiety disorder was clear,
the total prevalence rate was uncertain. Therefore,
we estimated the total cost of anxiety disorders by
adding the costs calculated for each anxiety disorderbased on the prevalence rate of each anxiety dis-
order. Furthermore, concerning the mortality cost,
the data for the rate of suicides among persons with
each anxiety disorder was obtained from Kaga’s re-
search [26]. However, in this research, suicides were
counted as being caused by anxiety disorders even in
patients with other coexisting disease. Thus, the re-
sults might have been overestimated. Furthermore, a
human capital approach was adopted when evaluat-
ing the mortality cost. Compared with a friction ap-
proach [29], this method is likely to overestimate the
impact.
Another limitation is the direct cost estimation. We
had to assume that the average healthcare cost for
anxiety disorders was the same as that for all F4
group disorders because of the lack of data regarding
costs specific to anxiety disorders. However, this as-
sumption might have caused an overestimation or an
underestimation of healthcare costs, since the F4
group of disorders includes not only anxiety disorders
but also other disorders, such as somatoform disor-
ders, dissociative disorders, post-traumatic stress dis-
orders, and so on, and service use by individuals with
these disorders might differ from those with anxiety
disorders.
Finally, the cost caused by all anxiety disorders was es-
timated in this study, even though it was revealed that
the prevalence rate or the number of days of suspension
from business differed among the various anxiety disor-
ders. Thus, more precise suggestions for reducing indir-
ect costs could likely be made if each anxiety disorder
were to be considered in greater detail. This may be an
important subject of study in the future.
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